Disease · MONDO_0019465

nodal marginal zone B-cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nodal marginal zone B-cell lymphoma. Diseases, record MONDO_0019465. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019465

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nodal marginal zone B-cell lymphoma; Open Targets
Open Targets ID: MONDO_0019465; Open Targets
Other names: Monocytoid B-cell lymphoma, NMZL, nodal marginal zone B-cell lymph., nodal marginal zone lymphoma; Open Targets
Disease Ontology: DOID:0080211; Disease Ontology
NCI Thesaurus: C8863; NCI Thesaurus
Orphanet: ORPHA:86867; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MOSUNETUZUMAB	CHEMBL4297788	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ACALABRUTINIB	CHEMBL3707348	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IBRITUMOMAB TIUXETAN	CHEMBL1201606	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ORELABRUTINIB	CHEMBL4650321	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TAFASITAMAB	CHEMBL4298047	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
UBLITUXIMAB	CHEMBL2108354	Antibody	Phase 1/2	TTD	1	0	0	Drugs and targets

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BTK	Tyrosine-protein kinase BTK	3	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
CD19	B-lymphocyte antigen CD19	1	B-lymphocyte antigen CD19 binding agent	Phase 2	https://conductscience.org/library/genes/930	Drugs and targets
CD3D	T cell surface glycoprotein CD3	1	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	1	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	1	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/917	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/1642	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/9978	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00493454	Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas	Phase 2	6	2013-05-31	Lymphoma	IBRITUMOMAB TIUXETAN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06006117	Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	Phase 3	260		Marginal Zone Lymphoma	LENALIDOMIDE, MOSUNETUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03697512	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas	Phase 2	175		Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma	IBRUTINIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT07448324	Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL	Phase 2	50		Marginal Zone Lymphoma(MZL)	LENALIDOMIDE, ORELABRUTINIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT04646395	Study of Acalabrutinib and Tafasitamab in MZL Patients	Phase 2	26		Marginal Zone Lymphoma	ACALABRUTINIB, TAFASITAMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
40550489	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019465

GET https://conductscience.org/api/diseases/v1/MONDO_0019465/drugs

API reference For AI assistants